Nakajima, W.; Miyazaki, K.; Sakaguchi, M.; Asano, Y.; Ishibashi, M.; Kurita, T.; Yamaguchi, H.; Takei, H.; Tanaka, N.
Epigenetic Priming with Decitabine Augments the Therapeutic Effect of Cisplatin on Triple-Negative Breast Cancer Cells through Induction of Proapoptotic Factor NOXA. Cancers 2022, 14, 248.
https://doi.org/10.3390/cancers14010248
AMA Style
Nakajima W, Miyazaki K, Sakaguchi M, Asano Y, Ishibashi M, Kurita T, Yamaguchi H, Takei H, Tanaka N.
Epigenetic Priming with Decitabine Augments the Therapeutic Effect of Cisplatin on Triple-Negative Breast Cancer Cells through Induction of Proapoptotic Factor NOXA. Cancers. 2022; 14(1):248.
https://doi.org/10.3390/cancers14010248
Chicago/Turabian Style
Nakajima, Wataru, Kai Miyazaki, Masahiro Sakaguchi, Yumi Asano, Mariko Ishibashi, Tomoko Kurita, Hiroki Yamaguchi, Hiroyuki Takei, and Nobuyuki Tanaka.
2022. "Epigenetic Priming with Decitabine Augments the Therapeutic Effect of Cisplatin on Triple-Negative Breast Cancer Cells through Induction of Proapoptotic Factor NOXA" Cancers 14, no. 1: 248.
https://doi.org/10.3390/cancers14010248
APA Style
Nakajima, W., Miyazaki, K., Sakaguchi, M., Asano, Y., Ishibashi, M., Kurita, T., Yamaguchi, H., Takei, H., & Tanaka, N.
(2022). Epigenetic Priming with Decitabine Augments the Therapeutic Effect of Cisplatin on Triple-Negative Breast Cancer Cells through Induction of Proapoptotic Factor NOXA. Cancers, 14(1), 248.
https://doi.org/10.3390/cancers14010248